tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Immatics NV

IMTX
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
6.390USD
-0.130-1.99%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
972.75M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Immatics NV ์ •๋ณด ํšŒ์‚ฌ

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Immatics NV ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ IMTX
ํšŒ์‚ฌ ์ด๋ฆ„Immatics NV
์ƒ์žฅ์ผJul 02, 2020
CEOSingh (Harpreet)
์ง์› ์ˆ˜297
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJul 02
์ฃผ์†ŒPaul Ehrlich-Strasse 15
๋„์‹œTUEBINGEN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Germany
์šฐํŽธ ๋ฒˆํ˜ธ72076
์ „ํ™”4970715397700
์›น์‚ฌ์ดํŠธhttps://immatics.com/
์ข…๋ชฉ ์ฝ”๋“œ IMTX
์ƒ์žฅ์ผJul 02, 2020
CEOSingh (Harpreet)

Immatics NV์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Edward Sturchio, J.D.
Mr. Edward Sturchio, J.D.
General Counsel
General Counsel
300.63K
+33.47%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+38.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%
Mr. Paul Rutherford Carter
Mr. Paul Rutherford Carter
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
Temporary Non-Executive Director
Temporary Non-Executive Director
30.00K
+66.67%
Dr. Carsten J. Reinhardt, M.D., Ph.D.
Dr. Carsten J. Reinhardt, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Ms. Amie Krause
Ms. Amie Krause
Chief People Officer
Chief People Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Edward Sturchio, J.D.
Mr. Edward Sturchio, J.D.
General Counsel
General Counsel
300.63K
+33.47%
Mr. Arnd Christ
Mr. Arnd Christ
Chief Financial Officer
Chief Financial Officer
276.84K
+38.63%
Mr. Michael G. (Mike) Atieh
Mr. Michael G. (Mike) Atieh
Non-Executive Independent Director
Non-Executive Independent Director
130.00K
+32.93%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Immatics NV์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Immatics NV์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Steffen Walter, Ph.D.

Immatics NV(IMTX)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Immatics NV์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 191๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 101.84M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 75.94%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -17425391.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ